Samuraciclib
- Generic Name
- Samuraciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O
- CAS Number
- 1805833-75-3
- Unique Ingredient Identifier
- 46D4HS9ODA
- Background
Samuraciclib is under investigation in clinical trial NCT03363893 (Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies).
- Associated Conditions
- -
- Associated Therapies
- -
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT06125522
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸Clinical and Translational Research Unit (CTRU), Palo Alto, California, United States
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 48
- Registration Number
- NCT05963997
- Locations
- 🇺🇸
Site 38 - Northwestern University, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
🇺🇸Site 42 - Dana-Farber Cancer Institute, EDDC, Boston, Massachusetts, United States
🇺🇸Site 35 - Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 60
- Registration Number
- NCT05963984
- Locations
- 🇺🇸
Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida, United States
🇺🇸Mfsmc-Hjwci, Baltimore, Maryland, United States
🇺🇸Saint Luke's Cancer Institute, Kansas City, Missouri, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 510
- Registration Number
- NCT04802759
- Locations
- 🇺🇸
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States
🇺🇸Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.